Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription 14.01.2019 1 Anticancer Res 4 BMC Cancer 2 BMC Urol 1 Cancer 1 Cancer Res 1 Eur Radiol 7 Eur Urol 1 Genes Chromosomes Cancer 2 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Cell Physiol 1 J Clin Oncol 1 Magn Reson Imaging 1 Nat Rev Urol 1 Oncology 1 PLoS One 1 Proc Natl Acad Sci U S A 6 Prostate 2 Urol Int 5 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Anticancer Res

1. LI JR, Wang SS, Lin CH, DE Groat WC, et al
   Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.
   Anticancer Res. 2019;39:305-311.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

2. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
   Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
   BMC Cancer. 2019;19:18.
   PubMed     Text format     Abstract available
   
   
3. QIU X, Wang W, Li B, Cheng B, et al
   Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
   BMC Cancer. 2019;19:27.
   PubMed     Text format     Abstract available
   
   
4. HEIDENREICH A, Gillessen S, Heinrich D, Keizman D, et al
   Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
   BMC Cancer. 2019;19:12.
   PubMed     Text format     Abstract available
   
   
5. ALIBHAI SMH, Santa Mina D, Ritvo P, Tomlinson G, et al
   A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.
   BMC Cancer. 2019;19:2.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

6. JOHNSTON WL, Catton CN, Swallow CJ
   Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
   BMC Urol. 2019;19:4.
   PubMed     Text format     Abstract available
   
   
7. ANDIC F, Izol V, Gokcay S, Arslantas HS, et al
   Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study.
   BMC Urol. 2019;19:3.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

8. SONPAVDE G, Agarwal N, Pond GR, Nagy RJ, et al
   Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
   Cancer. 2019 Jan 8. doi: 10.1002/cncr.31959.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

9. VUMMIDI GIRIDHAR P, Williams K, VonHandorf AP, Deford PL, et al
   Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
   Cancer Res. 2019 Jan 9. pii: 0008-5472.CAN-18-1753.
   PubMed     Text format     Abstract available
   
   

   
   Eur Radiol

10. DOMACHEVSKY L, Goldberg N, Bernstine H, Nidam M, et al
    Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
    Eur Radiol. 2018;28:5275-5283.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

11. HERLEMANN A, Cowan JE, Carroll PR, Cooperberg MR, et al
    Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;73:215-223.
    PubMed     Text format     Abstract available
    
    
12. BRZEZNIAK C, Oronsky B, Aggarwal R
    A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Eur Urol. 2018;73:306-307.
    PubMed     Text format    
    
    
13. HEIDEGGER I, Pichler R
    Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asia
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31049.
    PubMed     Text format    
    
    
14. KRETSCHMER A, Gleave ME
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31043.
    PubMed     Text format    
    
    
15. VIS AN, Boeve LMS
    Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31029.
    PubMed     Text format    
    
    
16. CIRIACO P, Briganti A, Bernabei A, Gandaglia G, et al
    Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31035.
    PubMed     Text format     Abstract available
    
    
17. MURPHY DG, Azad AA, Sandhu S, Violet J, et al
    Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31047.
    PubMed     Text format    
    
    

    
    Genes Chromosomes Cancer

18. KLUTH M, Abdelaziz Z, Ozden C, Hussein K, et al
    5q21 deletion is often heterogeneous in prostate cancer.
    Genes Chromosomes Cancer. 2019 Jan 9. doi: 10.1002/gcc.22730.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

19. LIU Q, Wang G, Li Q, Jiang W, et al
    Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32118.
    PubMed     Text format     Abstract available
    
    
20. SAMPSON N, Brunner E, Weber A, Puhr M, et al
    Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.
    Int J Cancer. 2018;143:383-395.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

21. ZELEFSKY MJ, Kollmeier M, McBride S, Varghese M, et al
    5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients with Low and Intermediate Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jan 3. pii: S0360-3016(18)34227.
    PubMed     Text format     Abstract available
    
    
22. GLICKSMAN R, Sanmamed N, Thoms J, Zlotta AR, et al
    A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.
    Int J Radiat Oncol Biol Phys. 2019 Jan 6. pii: S0360-3016(19)30001.
    PubMed     Text format     Abstract available
    
    

    
    J Cell Physiol

23. LIU DC, Song LL, Liang Q, Hao L, et al
    Long noncoding RNA LEF1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via LEF1 repression.
    J Cell Physiol. 2019 Jan 5. doi: 10.1002/jcp.27893.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

24. CASTRO E, Romero-Laorden N, Del Pozo A, Lozano R, et al
    PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Jan 9:JCO1800358. doi: 10.1200/JCO.18.00358.
    PubMed     Text format     Abstract available
    
    

    
    Magn Reson Imaging

25. OGURA A, Maeda F, Yahata S, Koyama D, et al
    Slow component apparent diffusion coefficient for prostate cancer: Comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging.
    Magn Reson Imaging. 2019 Jan 7. pii: S0730-725X(18)30524.
    PubMed     Text format     Abstract available
    
    

    
    Nat Rev Urol

26. BRADLEY CA
    Evolutionary and clinical trajectories of early-onset prostate cancer.
    Nat Rev Urol. 2019 Jan 4. pii: 10.1038/s41585-019-0144.
    PubMed     Text format    
    
    

    
    Oncology

27. FENG LR, Fuss T, Dickinson K, Ross A, et al
    Co-Occurring Symptoms Contribute to Persistent Fatigue in Prostate Cancer.
    Oncology. 2019 Jan 9:1-9. doi: 10.1159/000494620.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

28. FONSECA-ALVES CE, Kobayashi PE, Rivera Calderon LG, Felisbino SL, et al
    Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    PLoS One. 2018;13:e0199173.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

29. LORENZO G, Hughes TJR, Dominguez-Frojan P, Reali A, et al
    Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.
    Proc Natl Acad Sci U S A. 2019 Jan 7. pii: 1815735116.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

30. HATANAKA Y, de Velasco MA, Oki T, Shimizu N, et al
    HOXA10 expression profiling in prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23761.
    PubMed     Text format     Abstract available
    
    
31. PAPANICOLAU-SENGOS A, Yang Y, Pabla S, Lenzo FL, et al
    Identification of targets for prostate cancer immunotherapy.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23756.
    PubMed     Text format     Abstract available
    
    
32. FAN L, Yang Y, Chi C, Ma X, et al
    Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23762.
    PubMed     Text format     Abstract available
    
    
33. LIU Y, Wu X, Jiang H
    Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23760.
    PubMed     Text format     Abstract available
    
    
34. ZHAO M, Qi M, Li X, Hu J, et al
    CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23754.
    PubMed     Text format     Abstract available
    
    
35. BROADFIELD LA, Marcinko K, Tsakiridis E, Zacharidis PG, et al
    Salicylate enhances the response of prostate cancer to radiotherapy.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23755.
    PubMed     Text format     Abstract available
    
    

    
    Urol Int

36. XIANG C, Liu X, Chen S, Wang P, et al
    Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience.
    Urol Int. 2018;101:47-55.
    PubMed     Text format     Abstract available
    
    
37. HASHIMOTO M, Matsumura N, Ohzeki T, Hongo S, et al
    The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis.
    Urol Int. 2018;101:74-79.
    PubMed     Text format     Abstract available
    
    

    
    Urology

38. AGARWAL DK, Miest TS, Granberg CF, Frank I, et al
    Pediatric Robotic Prostatectomy and Pelvic Lymphadenectomy for Embryonal Rhabdomyosarcoma.
    Urology. 2018;119:143-145.
    PubMed     Text format     Abstract available
    
    
39. KAOUK JH, Garisto J, Sagalovich D, Dagenais J, et al
    Robotic Single-port Partial Prostatectomy for Anterior Tumors: Transvesical Approach.
    Urology. 2018;118:242.
    PubMed     Text format     Abstract available
    
    
40. ALPERT PF
    New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients.
    Urology. 2018;118:119-126.
    PubMed     Text format     Abstract available
    
    
41. EGGENER S, Karsh LI, Richardson T, Shindel AW, et al
    A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    Urology. 2019 Jan 3. pii: S0090-4295(19)30001.
    PubMed     Text format     Abstract available
    
    
42. MONDA SM, Vetter JM, Andriole GL, Fowler KJ, et al
    Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion.
    Urology. 2018;119:115-120.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: